Skin Cancer: Melanoma

    Actionable Target Abnormality Prevalence (%) Clinical Experience with Targeted Agent
    BRAF Mutation 44–48 (1,2) Vemurafenib (BRAF inhibitor):
    • Phase 3: RR 48% vs. 5% dacarbazine; mOS 13.6 vs. 10.3 mo with dacarbazine (3,4)
    Dabrafenib (BRAF inhibitor):
    • Phase 3: RR 50%, PFS 5.1 vs. 2.7 mo with dacarbazine (5)
    Dabrafenib  trametinib (BRAF and MEK inhibitors):
    • Phase 3: RR 67%, PFS 9.3 vs. 8.8 mo with dabrafenib (6)
    • Phase 3: RR 64%, PFS 11.4 vs. 7.3 mo with vemurafenib (7)
    Vemurafenib  cobimetinib (BRAF and MEK inhibitors):
    • Phase fenib (8)
    Other topics in Targets by Organ Site